Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04860505 · ClinicalTrials.gov registry record · Phase 4

Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

A Phase 4 study of Sexually Transmitted Diseases, sponsored by Emory University.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT04860505 is a Phase 4 study of Sexually Transmitted Diseases that has completed, run by Emory University. The registered enrollment target is 20 participants, below the 1,250-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04860505, a Phase 4 study of Sexually Transmitted Diseases, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).

Interventions

  • DRUG Doxycycline
  • DRUG Biktarvy

Study Locations (1)

Georgia

  • Hope Clinic - Atlanta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-05-20
Est. Completion 2022-05-09
Phase Phase 4

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT04860505

The ClinicalTrials.gov registry entry for NCT04860505 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,250-participant average among 35 other Sexually Transmitted Diseases trials with a reported enrollment target (98% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sexually Transmitted Diseases appearing as the primary indexed condition, and to 2 interventions - of which Doxycycline is the first listed.

NCT04860505 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT04860505 about?

NCT04860505 is a clinical study titled "Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens". The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).

What is the current status of trial NCT04860505?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2021-05-20. Estimated completion is 2022-05-09.

What conditions does trial NCT04860505 study?

This clinical trial studies the following conditions: Sexually Transmitted Diseases.

What interventions are being tested in trial NCT04860505?

The interventions under investigation include: Doxycycline (DRUG), Biktarvy (DRUG).

Who is sponsoring clinical trial NCT04860505?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04860505 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sexually Transmitted Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.